Alba Ramírez-Sarmiento

Alba Ramírez-Sarmiento

Auto-generated profile, based on publicly available information

Alba Ramírez-Sarmiento

Servicio de Neumología, Centro para el Cuidado de la Salud Respiratoria Hospital Internacional de Colombia‐Fundación Cardiovascular de Colombia FCV‐Fundación Universitaria FCV, Floridablanca, Santander, Colombia, and “EMICON” Research Group, Ministerio de Ciencia y Tecnología (MINCIENCIAS) Bogotá Colombia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
CCClaudia Colmenares-Mejía
Claudia Colmenares-Mejía
JRJessica Ruíz
Jessica Ruíz
YVYurley Dayanna Valencia-Barón
Yurley Dayanna Valencia-Barón
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
NSNorma C. Serrano
Norma C. Serrano
Chronic obstructive pulmonary disease (COPD) is a common, preventable, treatable lung disease characterized by persistent respiratory symptoms and airflow limitation and multiorgan impact. This affects the nutritional status of patients and requires multidimensional interventions including nutritional interventions according to individual metabolic needs. Our scoping review determined the effects of antioxidants in the treatment of COPD patients and their role in the decrease in the probability of exacerbations, hospital readmissions, and changes in lung function. The sources MEDLINE, LILACS, and Google Scholar were consulted and 19 studies were selected. The most indicated antioxidants are N-Acetylcysteine, vitamins E and D, and Zinc. Other antioxidants from plants or fruits extracts are also being investigated. The beneficial effect of antioxidants in stable or exacerbated patients is not clear, but theoretical and biological arguments of benefit justify lines of research that specify the impact on reducing oxidative stress and negative effects in COPD.

1 April 2004 in Medicina Clinica
Verified
Journal Article
Closed access
JMJuana M Martínez-Llorens
Juana M Martínez-Llorens
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
MMMaría José Masdeu
María José Masdeu
CCCarlos Coronell
Carlos Coronell
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
Joaquim GeaJoaquim Gea
Joaquim Gea

1 January 2021 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
OAOrlando Aya
Orlando Aya
DCDiana Cáceres-Rivera
Diana Cáceres-Rivera
CRCarlos F Reyes
Carlos F Reyes
AEAngela Espitia
Angela Espitia
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
Background: Bronchoaspiration of content that accumulates in the supraglottic area (eg, saliva, gastroesophageal reflux) is a risk factor for ventilator-associated pneumonia. A continuous supraglottic suction system may decrease the risk of bronchoaspiration in these patients. Objective: (1) Constructing a conceptual model and functional prototype of a continuous supraglottic suction device for use in humans; (2) defining functional characteristics in ex vivo swine head models; and (3) evaluating its efficacy and safety in mechanically ventilated patients. Methods: Study conducted in three phases. First phase: definition of distances and diameters of the triangle determined by dental arch, posterior oropharynx and vallecula, and diameter of the oropharynx in axial projection; and identification of the declining area of supraglottic suction. Second phase: design engineering and functional prototype evaluated in ex vivo models. Third phase: evaluation of device use in terms of safety and efficacy in ventilated patients. Results: We obtained a final functional model of the SUPRAtube device injected into PVC for medical use. Device effectiveness in in vitro simulation showed a high and fast suction capacity of liquid and thick volumes. Study of swine heads allowed to validate the shape, size and functional fenestration of the device. Study in intubated and mechanically ventilated patients showed a high supraglottic suction capacity and the absence of local adverse events during 72 (7-240) hours of continuous operation. Conclusion: Our study describes the process of conceptualization, design and production of a practical, safe, low-cost continuous supraglottic suction device without representing anti-biotic pressure, which appears to be a new complementary preventive strategy for the standard management of intubated and mechanically ventilated patients.

13 October 2022 in Revista Cuidarte
Verified
Journal Article
Open access
PDF file
MPMabel Magoth Reyes Pulido
Mabel Magoth Reyes Pulido
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
ASAlba Lucía Ramírez Sarmiento
Alba Lucía Ramírez Sarmiento
AGAngelica Julieth Nariño Gamboa
Angelica Julieth Nariño Gamboa
AIAndry Giseth Fragozo Ibarra
Andry Giseth Fragozo Ibarra
Introducción: Los procedimientos de traqueostomía van en aumento en las unidades de cuidados intensivos en el adulto, por lo que las complicaciones asociadas a este procedimiento también incrementan. Se ha identificado que la traqueostomía puede conllevar a complicaciones tanto preoperatorias como postoperatorias, que varían ampliamente entre un 5-40%, entre las más frecuentes están, estenosis traqueal, fístula traqueoesofágica, hemorragia, lesión peristomal, decanulación, infecciones, entre otras, que podrían causar la muerte hasta en 1,4% de las personas. Sin embargo, a nivel mundial muy pocos estudios abordan los conceptos causales o factores de riesgo mecánicos y no mecánicos de este importante tema. Objetivo: Revisar el alcance de la literatura científica disponible sobre las complicaciones de origen mecánico y no mecánico asociadas a la traqueostomía en pacientes adultos en las unidades de cuidados intensivos entre el periodo 2015-2020. Materiales y métodos: se establecieron la pregunta de investigación con metodología “Patient, Intervention, Comparation, Outcome, Time (PICOT)” y los criterios de inclusión para la búsqueda de los referentes bibliográficos de estudios observacionales y experimentales. La información fue consultada en las bases de datos PubMed y EBSCO y los artículos científicos seleccionados fueron los publicados entre los años 2015-2020. Como guía metodológica y de calidad para el presente estudio se utilizó la lista de chequeo PRISMA-ScR. Resultados: las complicaciones con mayor frecuencia son: sangrado 61% presentada (13/21 artículos), estenosis traqueal 28,5% (5/21 artículos), decanulación 23,6% (5/21 artículos), infección de la estoma 19% (4/21 artículos) muerte 19% (4/21) y la dificultad en la inserción de la cánula 19% (4/21 artículos), en cuanto a factores de riesgo mecánicos para éstas sólo se identifica el uso de la técnica Bjork flap (OR=0,4). Entre los no mecánicos se encontraron, obesidad (OR=5,15), diámetro de cánula >6 (OR= 2,6) y ventilación mecánica preoperatoria (OR=3,14). Conclusión:Se logró identificar que las complicaciones relacionadas con la traqueostomía con mayor incidencia son sangrado, estenosis traqueal, decanulación accidental y la muerte. Sin embargo, aún se desconoce si se originan por una causa mecánica o no mecánica durante su manejo en UCI. Como citar este artículo: Reyes Pulido Mabel Magoth, Orozco Levi Mauricio, Ramírez Sarmiento Alba Lucía, Nariño Gamboa Angelica Julieth, Fragozo Ibarra Andry Giseth. Complicaciones en pacientes usuarios de traqueostomía en unidades de cuidados intensivos. Scoping Review. Revista Cuidarte. 2022;13(3):e2281. http://dx.doi.org/10.15649/cuidarte.2281     

1 March 2025 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
DTDiana Carolina Tiga-Loza
Diana Carolina Tiga-Loza
OAOrlando Aya
Orlando Aya
CRCarlos Fernando Reyes
Carlos Fernando Reyes
DCDiana Cáceres-Rivera
Diana Cáceres-Rivera
ARAlba Ramírez-Sarmiento
Alba Ramírez-Sarmiento
Objective: To evaluate the efficacy and safety of the SUPRAtube innovation device in preventing ventilator associated events and fluid accumulation in the supraglottic region in patients receiving mechanical ventilation (MV) through orotracheal tubes. Methods: Multicenter, controlled, randomized, parallel, open-label clinical trial with a 1:1 allocation ratio of MV patients compared the use of the SUPRAtube elastomeric device with standard care and aspiration techniques. A series of computer-random numbers and centralized allocation with sealed envelopes were used. Setting: Adult patients (n=108; mean age: 63 yrs, range: 19– 85) hospitalized in intensive care units of two centers, the Cardiovascular Foundation of Colombia and the International Hospital of Colombia (Santander, Colombia), were included. All patients received MV through orotracheal tubes, were hemodynamically stable, had upper airway integrity according to fiberoptic bronchoscope findings, and had basic coagulation tests within acceptable risk criteria. Interventions: Comprehensive standard of care, including preventive strategies, medical therapy, positive pressure MV, and routine procedures for management of oropharyngeal and pulmonary secretions (humidification, patient mobilization, and airway suctioning), was compared with the standard of care plus continuous supraglottic suction with the new SUPRAtube device. Results: The study period reached five days before extubation (media 85± 7 hours). The weight of the aspirated content was 415 g (P25;P75: 396;536) in the control group and 624 g (P25;P75: 469;824) in the SUPRAtube group (p< 0.001), equivalent to a mean difference of 213 g (P25;P75: 55;569; +50%). The device did not induce adverse events. Conclusion: Continuous supraglottic aspiration using SUPRAtube is complementary, effective, safe, simple, and inexpensive and reduces the accumulation of oropharyngeal secretions in mechanically ventilated patients. The relevant clinical benefit in terms of preventing and improving tracheobronchitis earlier on was demonstrated by sequential fiberoptic bronchoscopy. Registration in Clinical Trials: The present study is registered at clinicaltrials.gov NCT03573609.

1 October 2025 in Pulmonary Circulation
Verified
Journal Article
Open access
MOMauricio Orozco-Levi
Mauricio Orozco-Levi
VPVinicio A. de Jesus Perez
Vinicio A. de Jesus Perez
TPTomas Pulido
Tomas Pulido
APAngie Pabón‐Quezada
Angie Pabón‐Quezada
PMPhilip Morisky
Philip Morisky
ARAlba Ramírez‐Sarmiento
Alba Ramírez‐Sarmiento
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life‐threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher. Paradoxically, while early detection of PAH is strongly encouraged to preempt irreversible vascular, cardiac, and multisystem damage, treatment remains largely restricted to those already exhibiting symptoms. Patients in NYHA class I, though experiencing pathophysiological progression, are systematically excluded from approved pharmacological therapies. This disjunction represents not only a clinical and ethical conundrum but also a conceptual paradox: why invest in early diagnosis if early treatment is withheld? Emerging evidence on various chronic diseases, including cancer, infectious diseases like HIV and hepatitis, and even other cardiovascular diseases, underscores the benefits of initiating treatment before the onset of symptoms. In contrast, the current approach to PAH inadvertently promotes a nihilistic “wait and see” policy, exposing asymptomatic patients to preventable deterioration. Herein, we call for a reassessment of clinical guidelines, regulatory frameworks, and access policies with the goal of better aligning them with the biological realities of PAH. While we advocate for a paradigm shift toward the inclusion of NYHA class I patients in treatment strategies, we explicitly acknowledge the current limitations of the evidence base and emphasize the need for ongoing, high‐quality research including counterarguments and the practical challenges of early treatments.